On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

TYMP

thymidine phosphorylase

Chromosome 22q13.33 Autosomal recessive HGNC:3148 Tier C
TYMP 22q13.33 p arm q arm 22

TYMP is located on the long (q) arm of chromosome 22, at band 22q13.33. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 22 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The TYMP gene, located on chromosome 22, encodes thymidine phosphorylase, an enzyme critical for regulating nucleoside metabolism throughout the body. This 482-amino-acid protein catalyses the breakdown of thymidine into smaller molecules, preventing nucleoside accumulation that could interfere with mitochondrial function. Pathogenic variants in TYMP follow an autosomal recessive inheritance pattern and are the sole cause of mitochondrial neurogastrointestinal encephalopathy (MNGIE), a progressive disorder characterised by gastrointestinal dysmotility, peripheral neuropathy, and mitochondrial DNA depletion.

TYMP was previously known as ECGF1 (endothelial cell growth factor 1) due to its angiogenic properties, though its primary recognised function relates to nucleoside metabolism. The gene appears on multiple NHS Genomic Medicine Service panels for mitochondrial disorders, metabolic conditions, and neuropathies, reflecting the diverse clinical presentations of TYMP-related disease.

What the gene does

Thymidine phosphorylase enables the breakdown of thymidine, a nucleoside molecule. Once chemically modified, thymidine serves as a DNA building block. The enzyme splits thymidine into thymine and 2-deoxyribose 1-phosphate, thereby controlling how much of this nucleoside is present in cells. This regulatory function proves especially important within mitochondria, the cellular structures responsible for energy conversion from food.

Mitochondria house their own small DNA genome, distinct from the chromosomal DNA in the cell nucleus. To replicate this mitochondrial DNA, mitochondria require nucleosides such as thymidine. The thymidine phosphorylase enzyme ensures that mitochondria maintain suitable nucleoside quantities for building new DNA molecules. Without adequate enzyme activity, nucleoside levels become unbalanced, which can compromise mitochondrial DNA synthesis and the overall function of these energy-producing structures.

Video: Genetics 101

Chromosome location

TYMP is located on the long arm of chromosome 22 at position 22q13.33, near the telomeric region of the chromosome. This chromosomal region contains numerous genes involved in metabolic and developmental processes. The gene's position in the distal portion of chromosome 22 places it within a genomic segment that has been associated with various copy number variations, though TYMP-related disease typically results from point mutations rather than large deletions.

Protein structure

The thymidine phosphorylase protein comprises 482 amino acids with several notable structural features. The N-terminal region contains a disordered segment spanning amino acids 1-36, which likely provides flexibility for protein interactions or regulatory functions. The protein contains multiple R-V-A-A-A-L-X(5,6)-L-G-R repeats at positions 265-279 and 329-342, which may contribute to substrate recognition or catalytic activity. Additionally, two R-A-L-X-X-A-L-V-L repeats are present at amino acids 393-401 and 453-461, potentially involved in structural stability or protein-protein interactions. These repetitive elements suggest a modular organisation that may facilitate the enzyme's catalytic function and cellular localisation.

Domain map · 482 amino acids
R-V-A-A-A-L-X(5,6)-L-G-R (265-279)R-V-A-A-A-L-X(5,6)-L-G-R (329-342)R-A-L-X-X-A-L-V-L (393-401)R-A-L-X-X-A-L-V-L (453-461)R-V-A-A-A-L-X265-279R-V-A-A-A-L-X329-342R-A-L-X-X-A-L-V-L393-4011~241482
Repeat - repeating structural motif
🧬 Explore 3D structure on AlphaFold
UniProt:P19971Length:482 aaStructure:AlphaFold

Key variants

Approximately 50 different pathogenic variants in TYMP have been identified in individuals with mitochondrial neurogastrointestinal encephalopathy. These variants typically result in severely reduced or completely absent thymidine phosphorylase enzyme activity. The majority of disease-causing changes are missense variants, nonsense variants, or small deletions that disrupt the protein's catalytic function. Because MNGIE follows autosomal recessive inheritance, affected individuals carry pathogenic variants on both copies of the gene, whilst heterozygous carriers typically remain asymptomatic.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for TYMP.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.298C>T
single nucleotide variant
p.Gln100Ter Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.323G>A
single nucleotide variant
p.Trp108Ter Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.434_437dup
Duplication
p.Gly147fs Pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.52_53del
Deletion
p.Phe18fs Pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.536_539dup
Duplication
p.Cys182fs Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.554_561del
Deletion
p.Val185fs Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.61G>T
single nucleotide variant
p.Glu21Ter Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial neurogastrointestinal encephalomyopathy
c.647-1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.739C>T
single nucleotide variant
p.Gln247Ter Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial DNA depletion syndrome 1
c.865_889dup
Duplication
p.Ala297fs Pathogenic/Likely pathogenic ★★☆☆ Mitochondrial neurogastrointestinal encephalomyopathy

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in TYMP cause MNGIE (mitochondrial neurogastrointestinal encephalopathy), a severe autosomal recessive disorder with typical onset between the second and fifth decades of life. The condition manifests with progressive gastrointestinal dysmotility leading to chronic diarrhoea, nausea, and severe weight loss, alongside peripheral neuropathy, ophthalmoplegia, and leukoencephalopathy. MNGIE results from the accumulation of thymidine and deoxyuridine in plasma and tissues, which disrupts mitochondrial DNA maintenance and causes progressive mitochondrial dysfunction in affected organs.

Inheritance pattern

Conditions caused by pathogenic TYMP variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous TYMP carrier status across ancestry groups?

UK clinical status

TYMP holds green classification status across 14 NHS Genomic Medicine Service gene panels, reflecting strong evidence for its clinical utility in diagnostic pathways. The gene appears on panels for mitochondrial neurogastrointestinal encephalopathy (R394), mitochondrial DNA maintenance disorder (R352), and likely inborn error of metabolism (R98). Additional panel memberships include adult onset leucodystrophy (R62), hereditary neuropathy or pain disorder (R78), possible mitochondrial disorder - nuclear genes (R63), gastrointestinal neuromuscular disorders, paediatric pseudo-obstruction syndrome (R438), rhabdomyolysis and metabolic muscle disorders, inherited white matter disorders, white matter disorders and cerebral calcification, undiagnosed metabolic disorders, and general mitochondrial disorders panels. This extensive panel representation underscores the diverse clinical presentations of TYMP-related disease and the importance of considering this gene in multiple diagnostic contexts.

Frequently asked questions

What is the difference between TYMP and MNGIE?

TYMP is the name of the gene that provides instructions for making thymidine phosphorylase enzyme, whilst MNGIE (mitochondrial neurogastrointestinal encephalopathy) is the disease caused when both copies of the TYMP gene carry pathogenic variants. The term MNGIE was previously used as an alternative name for the gene itself, which can cause confusion in older literature.

Can carriers of one TYMP variant develop symptoms?

Individuals who carry a single pathogenic TYMP variant (heterozygous carriers) typically do not develop symptoms of MNGIE, as the remaining functional copy of the gene produces sufficient thymidine phosphorylase enzyme. MNGIE follows autosomal recessive inheritance, meaning symptoms only manifest when both gene copies carry pathogenic variants.

Why does TYMP appear on so many different NHS panels?

MNGIE presents with a wide range of symptoms affecting multiple organ systems, including the gastrointestinal tract, peripheral nerves, brain white matter, eyes, and muscles. This diverse clinical presentation means TYMP is relevant to diagnostic pathways for mitochondrial disorders, neuropathies, gastrointestinal dysmotility, leucodystrophies, and metabolic conditions, resulting in its inclusion across numerous genomic medicine panels.

References

  1. Lara MC, Valentino ML, Torres-Torronteras J. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Bioscience reports. 2007. PMID: 17549623
  2. Valentino ML, Martí R, Tadesse S. Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS letters. 2007. PMID: 17612528
  3. Hirano M, Nishigaki Y, Martí R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. The neurologist. 2004. PMID: 14720311
  4. Hirano M, Martí R, Spinazzola A. Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder. Nucleosides, nucleotides & nucleic acids. 2004. PMID: 15571233
  5. Martí R, Nishigaki Y, Vilá MR. Alteration of nucleotide metabolism: a new mechanism for mitochondrial disorders. Clinical chemistry and laboratory medicine. 2003. PMID: 12940507
  6. Marti R, Spinazzola A, Nishino I. Mitochondrial neurogastrointestinal encephalomyopathy and thymidine metabolism: results and hypotheses. Mitochondrion. 2002. PMID: 16120316
  7. Nishino I, Spinazzola A, Hirano M. MNGIE: from nuclear DNA to mitochondrial DNA. Neuromuscular disorders : NMD. 2001. PMID: 11166160
  8. Nishino I, Spinazzola A, Papadimitriou A. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Annals of neurology. 2000. PMID: 10852545
  9. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science (New York, N.Y.). 1999. PMID: 9924029
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 17 April 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .